Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

State ADAPs Ask Manufacturers For Price Concessions; Fuzeon Fuels Effort

Executive Summary

State AIDS Drug Assistance Programs are asking all HIV therapy manufacturers for price breaks as they prepare to pick up coverage of Roche's Fuzeon

You may also be interested in...



State ADAPs secure higher Rx discounts

Abbott, Boehringer Ingelheim, Gilead and Merck agree to price concessions for state AIDS drug assistance programs. Abbott agreement provides supplemental rebates on full HIV/AIDS product line; BI says it will freeze Viramune price for two years. Companies join Roche in finalizing negotiations following Washington, D.C. meeting (1"The Pink Sheet" April 21, p. 7). Discussions with Pfizer/Agouron, GlaxoSmithKline and Bristol-Myers Squibb are ongoing, state directors say...

State ADAPs secure higher Rx discounts

Abbott, Boehringer Ingelheim, Gilead and Merck agree to price concessions for state AIDS drug assistance programs. Abbott agreement provides supplemental rebates on full HIV/AIDS product line; BI says it will freeze Viramune price for two years. Companies join Roche in finalizing negotiations following Washington, D.C. meeting (1"The Pink Sheet" April 21, p. 7). Discussions with Pfizer/Agouron, GlaxoSmithKline and Bristol-Myers Squibb are ongoing, state directors say...

Roche Fuzeon WAC

Wholesale acquisition cost of Roche/Trimeris' HIV agent Fuzeon (enfuvirtide) will be "just under $20,000 for one year's supply," the companies said. Roche Global Pharmaceutical Head William Burns said a settlement has been reached with state AIDS Drug Assistance Programs but "it is on terms that we are not releasing publicly." Roche used its broad antiretrovial portfolio as leverage in price negotiations with state ADAPs (1"The Pink Sheet" March 24, p. 35)...

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel